In this trial, including ATC patients mentioned above and another clinical trial of radioiodine-refractory (RAI-R) TC for BRAF V600E-mutant [10,81], the most common AEs of vemurafenib included rash, fatigue, arthralgia, alopecia, gastrointestinal reactions, hematologic toxicity, and serious AEs reported were cutaneous squamous cell carcinoma, keratoacanthoma, dyspnea, pneumonia, hypotension, and cerebrovascular accidents. Here, BRAF is linked to keratoacanthoma.